

REMARKS

Upon entry of the present amendment, claims 1 – 4, 6, 7, 11, 14 – 19, 21 – 26, and 29 – 31 are pending. Claims 5, 8 - 10, 12, 13, 20, 27, 28 and 32 – 37 have been cancelled. Claim 31 has been amended to further define a factor VII-responsive syndrome. Basis for the amendment can be found in the Specification as originally filed, and in particular in paragraphs [0048] and [0073] of US Patent Application Publication No. 20040037893. The present amendment adds no new matter.

THE NON-STATUTORY DOUBLE PATENTING REJECTION

The Examiner has rejected claims 1 – 4, 6, 7, 11, 14 – 19, 21 – 26 and 29 – 31 on the grounds of non-statutory obviousness-type double patenting as being unpatentable over claims 1 – 10 of U.S. Patent No. 6,833,352.

Applicants file herewith a Terminal Disclaimer. Accordingly, Applicants believe that the present rejection is now moot.

Conclusion

In view of the above, Applicant(s) submit(s) that the application is now in condition for allowance and issue and respectfully request(s) early action to that end. Applicant(s) believe(s) that no additional fees are due. However, should any fees be due, the Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The undersigned invites the Examiner to contact her by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 18, 2009

/Shelby J. Walker, Reg. No. 45,192/
Shelby J. Walker, Reg. No. 45,192
Novo Nordisk Inc.
Customer Number 23650
(609) 987-4883